The Pulse Magazine

Skip to content

The Archive

All Stories

Journeys, strategies and ideas from the people redefining business, leadership and innovation.

Cochrane review anti-amyloid Alzheimer's drugs Leqembi Kisunla trivial effects 2026
Health & Wellness

Anti-Amyloid Alzheimer’s Drugs Face New Doubts: Cochrane Review Finds ‘Trivial’ Effects

A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.

Reed Hastings Netflix co-founder board chair departure 2026
News

Reed Hastings Steps Down as Netflix Board Chair: What It Means for Investors in 2026

Reed Hastings, the legendary co-founder and longtime chair of Netflix, is stepping down from the board in June 2026. This news comes as Netflix reports strong Q1 earnings and moves on from its failed $72 billion Warner Bros Discovery acquisition. Netflix Confirms No Disagreements in Reed Hastings Departure In an SEC filing and shareholder letter